ReleaseWire

Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing

An investigation on behalf of investors in Athira Pharma, Inc. (NASDAQ:ATHA) shares over potential wrongdoing at Athira Pharma, Inc. was announced.

Posted: Monday, March 06, 2023 at 11:30 AM CST

San Diego, CA -- (SBWire) -- 03/06/2023 --An investigation was announced over potential breaches of fiduciary duties by certain directors at Athira Pharma, Inc. .

Investors who purchased shares of Athira Pharma, Inc. (NASDAQ: ATHA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Athira Pharma, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

On June 25, 2021, a lawsuit was filed for investors in shares of Athira Pharma, Inc over alleged Securities Laws Violations. The plaintiff claims the Registration Statement and that between September 18, 2020 and June 17, 202, the defendants made materially false and misleading statements and omitted to state that Dr. Kawas had published research papers containing improperly altered images while she was a graduate student, that this purported research was foundational to Athira's efforts to develop treatments for Alzheimer's because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer's, that as a result, Athira's intellectual property and product development for the treatment of Alzheimer's was based on invalid research, and that as a result of the foregoing, the defendants' positive statements about Athira's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On January 7, 2022, a consolidated amended complaint was filed and on March 8, 2022, the defendants filed their motion to dismiss the case.

On July 29, 2022, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

Those who purchased shares of Athira Pharma, Inc. (NASDAQ: ATHA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.